# Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

> **NCT02946554** · PHASE2 · COMPLETED · sponsor: **Cellaion SA** · enrollment: 24 (actual)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **BIOLOGICAL:** HepaStem

## Key facts

- **NCT ID:** NCT02946554
- **Lead sponsor:** Cellaion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02946554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02946554, "Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02946554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*